KNE Kane Biotech Inc.

STEM Animal Health Appoints New President and CEO

STEM Animal Health Appoints New President and CEO
EN
13/10/2020

Underlying

KNEKane Biotech Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kane Biotech Inc.

 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Provides Further Corporate Update

Kane Biotech Provides Further Corporate Update WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase. The Company has terminated its exclusive distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) dated April 18, 2023 due to various material breaches by ProgenaCare of the agreement. Activities to resecure distribution for its products in the United States are underway. The Company recently received a notice of default from Prairies Economic Development ...

June 18, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Announces First Quarter 2025 Financial Results

Kane Biotech Announces First Quarter 2025 Financial Results WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results. First Quarter 2025 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended March 31, 2025 was $412,513 compared to $51,886 in the three months ended March 31, 2024. Revenue in the current quarter consists primarily of contract animal health manufacturing revenue for...

May 29, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Res...

Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended December 31,2024 was $125,859 compared to $57,788 in the three months ended December 31, 2023. F...

April 28, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acn...

Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review Board (“IRB”) of the University of Miami Health System (“UHealth”) to commence a clinical study of Kane’s prototype DispersinB® Acne Cleanser for the treatment of mild to moderate cases of Acne Vulgaris. The ...

March 13, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Announces Canadian Distribution Agreement With Best Buy M...

Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel Product line. In November 2024, Kane Biotech received Health Canada approval for its revyve™ Antimicrobial Wound Gel, marking a significant...

March 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch